Table 2 Pharmacokinetic parameters following single i.v. injection of CS1003 in cynomolgus monkey (mean ± SD, n = 6).
From: CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
Group | 2 mg/kg, i.v. | 6 mg/kg, i.v. | 18 mg/kg, i.v. |
|---|---|---|---|
C0 (µg/mL) | 58.9 ± 9.18 | 178 ± 47.5 | 492 ± 40.5 |
T1/2 (d) | 6.36 ± 2.83 | 5.67 ± 6.05 | 11.5 ± 3.25 |
Vdss (L/kg) | 0.0577 ± 0.0134 | 0.0514 ± 0.0124 | 0.0631 ± 0.00704 |
Cl (mL·d−1·k−1) | 6.80 ± 3.12 | 6.55 ± 2.50 | 3.98 ± 0.488 |
AUC0-last (µg•d/mL) | 310 ± 101 | 978 ± 358 | 3980 ± 323 |
AUC0-inf (µg•d/mL) | 331 ± 99.3 | 1070 ± 507 | 4580 ± 626 |
